3-(2,2,2-trimethylhydrazine)propionate has been researched along with cardiovascular agents in 78 studies
| Studies (3-(2,2,2-trimethylhydrazine)propionate) | Trials (3-(2,2,2-trimethylhydrazine)propionate) | Recent Studies (post-2010) (3-(2,2,2-trimethylhydrazine)propionate) | Studies (cardiovascular agents) | Trials (cardiovascular agents) | Recent Studies (post-2010) (cardiovascular agents) |
|---|---|---|---|---|---|
| 251 | 35 | 105 | 17,645 | 1,480 | 6,891 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.28) | 18.7374 |
| 1990's | 10 (12.82) | 18.2507 |
| 2000's | 31 (39.74) | 29.6817 |
| 2010's | 35 (44.87) | 24.3611 |
| 2020's | 1 (1.28) | 2.80 |
| Authors | Studies |
|---|---|
| Artiukh, VP; Sakharchuk, II; Sisetskiĭ, AP; Starodub, NF | 1 |
| Vinichuk, SM | 1 |
| Cherkasova, NA; Giliarovskiĭ, AK; Mikhaĭlov, AA; Simonov, VI; Zhelnov, VV | 1 |
| Artiukh, VP; Denisenko, GT; Sakharchuk, II; Sisetskiĭ, AP; Starodub, NF | 1 |
| Kovalev, GV; Spasov, AA; Tsibanev, AV | 1 |
| Dudko, VA; Koshel'skaia, OA; Sokolov, AA | 1 |
| Asaka, N; Kirimoto, T; Miyake, H; Muranaka, Y | 1 |
| Harashima, H; Hayashi, M; Ise, S; Kiwada, H; Kuwajima, M; Lu, Km; Sei, M; Shima, K; Sugiyama, Y | 1 |
| Kutuzova, AE; Nedoshivin, AO; Perepech, NB | 1 |
| Kutuzova, AE; Nedoshivin, AO; Perepech, NB; Petrova, NN | 1 |
| Asaka, N; Hayashi, Y; Kanno, T; Kirimoto, T; Matsuura, N; Miyake, H; Nakano, M | 1 |
| Asaka, N; Hayashi, Y; Kirimoto, T; Matsuura, N; Miyake, H; Nakano, M; Tajima, K | 1 |
| Esumi, Y; Kawaguchi, Y; Minami, Y; Saeki, M; Yamamoto, Y; Yoshida, K; Yoshisue, K | 1 |
| Hayashi, Y; Hoshiai, K; Hoshiai, M; Ishida, H; Kanno, T; Kirimoto, T; Matsuura, N; Miyake, H; Nakano, M; Nakazawa, H; Tajima, K | 1 |
| Aoyagi, T; Eto, Y; Hayashi, Y; Kirimoto, T; Matsumoto, A; Momomura, S; Omata, M; Sugiura, S; Yokoyama, I; Yonekura, K | 1 |
| Dambrova, M; Kalvinsh, I; Liepinsh, E | 1 |
| Maisch, B; Rupp, H; Zarain-Herzberg, A | 1 |
| Mamchur, SE; Sankevitch, TV; Stepatcheva, TA; Teplyakov, AT | 1 |
| Paleev, FN; Paleev, NR | 1 |
| André, A; Clouet, P; Degrace, P; Demaison, L; Demizieux, L; Gresti, J; Tsoko, M | 1 |
| Daĭia, D; Dambrova, M; Kalvin'sh, I; Kir'ianova, O; Liepin'sh, E | 1 |
| Arduini, A; Carminati, P; Giannessi, F; Giarrizzo, MG; Peschechera, A; Ricciolini, R; Russo, F; Scalibastri, M | 1 |
| Gutcaits, A; Kalvinsh, I; Sjakste, N | 1 |
| Böhm, M; Eckel, L; Grube, M; Haney, J; Jedlitschky, G; Kroemer, HK; Meissner, K; Meyer zu Schwabedissen, HE; Möritz, KU; Präger, D; Rosskopf, D | 1 |
| Golovacheva, MO | 1 |
| Glonti, TG; Gorgoshidze, ML; Svanidze, TD; Tsintsadze, IN | 1 |
| Kalvinsh, I; Kloner, RA; Sesti, C; Simkhovich, BZ | 1 |
| Megreladze, TI; Sakvarelidze, EP; Zakaraia, MV | 1 |
| Sakvarelidze, EP | 1 |
| Gordjushina, V; Isajevs, S; Kalvinsh, I; Klusa, V; Kratovska, A; Pupure, J; Rumaks, J; Svirskis, S; Taivans, I; Viksna, L | 1 |
| Bagdonas, G; Kalvinsh, I; Knasene, Iu; Lesaukaite, V; Matsiyauskene, Iu; Visokinskas, A | 1 |
| Dambrova, M; Kalvinsh, I; Kirjanova, O; Liepinsh, E; Loca, D; Pugovichs, O; Vilskersts, R | 1 |
| Bi, KS; Hu, X; Lv, YF | 1 |
| Iushchuk, EN; Khadzegova, AB; Sadulaeva, IA; Shkol'nik, EL; Vakhromeeva, MN; Vasiuk, IuA; Vit'ko, NK | 1 |
| Belenkova, SV; Shilina, NN; Sporova, OE; Statsenko, ME | 1 |
| Goncharova, EV; Govorin, AV | 1 |
| Apukhtin, AF; Dudchenko, GP; Poletaeva, LV; Statsenko, ME; Turkina, SV | 1 |
| Chlopicki, S; Dambrova, M; Grinberga, S; Kalvinsh, I; Liepinsh, E; Mateuszuk, L; Vilskersts, R | 1 |
| Aleksandrova, TS; Chibisov, SM; Gribanov, AN; Kariakina, TN; Kotliarov, AA; Mosina, LM | 1 |
| Cirule, H; Dambrova, M; Grinberga, S; Kalvinsh, I; Kuka, J; Liepinsh, E; Skapare, E; Svalbe, B; Vilskersts, R; Zvejniece, L | 1 |
| Cirule, H; Dambrova, M; Kalvinsh, I; Kuka, J; Liepinsh, E; Pugovics, O; Skapare, E; Svalbe, B; Vilskersts, R | 1 |
| Dambrova, M; Gutsaits, A; Jaudzems, K; Kalvinsh, I; Kuka, J; Liepinsh, E; Zinovjevs, K | 1 |
| Liu, Y; Luo, Z; Peng, Y; Wang, J; Wang, Z; Wen, A; Yang, J | 1 |
| Dambrova, M; Grinberga, S; Kalvinsh, I; Konrade, I; Kuka, J; Liepinsh, E; Pugovics, O; Skapare, E | 1 |
| Cirule, H; Dambrova, M; Grinberga, S; Kalvinsh, I; Kuka, J; Liepinsh, E; Svalbe, B; Vilskersts, R | 1 |
| Cirule, H; Dambrova, M; Kalvinsh, I; Kuka, J; Liepinsh, E; Makrecka, M; Pugovics, O; Vilskersts, R | 1 |
| Dzerve, V | 1 |
| Beitnere, U; Isajeva, D; Isajevs, S; Jansone, B; Kalvinsh, I; Klusa, V | 1 |
| Afanas'ev, VV; Murashko, NK | 1 |
| Cirule, H; Dambrova, M; Grinberga, S; Mezhapuke, R; Vilskersts, R; Zharkova-Malkova, O | 1 |
| Gorbach, TV; Kukes, VG; Romashchenko, OV; Rumbesht, VV; Zhernakova, NI | 1 |
| Fedorova, TN; Maksimova, MIu | 1 |
| Dambrova, M; Grinberga, S; Kalvins, I; Konrade, I; Liepins, E; Petrovska, R; Pugovics, O; Skapare-Makarova, E; Tirzite, D | 1 |
| Feng, L; Guo, Z; Li, D; Li, Z; Liu, J; Liu, X; Qu, F; Xia, J; Yan, X; Zhang, B; Zhang, G; Zhang, X; Zhang, Z; Zhao, G; Zhao, H; Zhao, J; Zhu, Y | 1 |
| Berzina-Cimdina, L; Loca, D; Makrecka, M; Sevostjanovs, E; Sokolova, M; Tupureina, V; Zharkova-Malkova, O | 1 |
| Petrov, AA; Petrova, VV; Rukavishnikov, IV | 1 |
| Actiņš, A; Bērziņš, A | 1 |
| Shilina, NN; Statsenko, ME; Turkina, SV | 2 |
| Drokina, OV; Druk, IV; Dubileĭ, GS; Nechaeva, GI | 1 |
| Ageev, FT; Konovalova, GN; Kuzmina, AE; Lankin, VZ; Smirnova, MD; Svirida, ON; Tikhaze, AK; Vitsenia, MV | 1 |
| Vatseba, MO | 1 |
| Ageev, FT; Forfanova, TV; Mikhaĭlov, GV; Smirnova, MD; Svirida, ON; Vitsenia, MV | 1 |
| Nechaeva, GI; Potashov, DA; Zheltikova, EN | 1 |
| Cherniatina, MA; Kharchenko, AV; Mikhin, VP; Panchenko, GV; Tsukanova, IuA | 1 |
| Chen, J; Chen, X; Chen, Z; Huang, M; Liang, Y; Ma, Z; Peng, W; Tang, H; Wang, X; Zhao, Z; Zhong, G | 1 |
| Nechaeva, GI; Zheltikova, EN | 1 |
| Dambrova, M; Kuka, J; Liepinsh, E; Makarova, E; Makrecka-Kuka, M; Vilskersts, R | 1 |
| Hawkes, N | 1 |
| Ermolenko, AA; Statsenko, ME; Turkina, SV | 1 |
| Arduini, A; Zammit, VA | 1 |
| Dambrova, M; Liepinsh, E | 1 |
| Jargin, SV | 1 |
| Karpov, ES; Lyamina, NP; Razborov, IB | 1 |
| Fabritskaya, SV; Shilina, NN; Statsenko, S; Turkin, SV | 1 |
| Berge, RK; Bjørndal, B; Hallström, S; Lindquist, C; Rossmann, CR; Svardal, A | 1 |
| Astrelina, T; Karkischenko, V; Miroshnikova, Y; Rabin, O; Razinkin, S; Samoylov, A; Semyonov, S; Uiba, V; Zabelin, M | 1 |
| Gryaznova, MV; Gureev, AP; Ignatyeva, DA; Popov, VN; Shaforostova, EA; Volodina, DE | 1 |
7 review(s) available for 3-(2,2,2-trimethylhydrazine)propionate and cardiovascular agents
| Article | Year |
|---|---|
Mildronate: cardioprotective action through carnitine-lowering effect.
Topics: Cardiotonic Agents; Cardiovascular Agents; Carnitine; Energy Metabolism; Humans; Methylhydrazines | 2002 |
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Topics: Acetanilides; Angina Pectoris; Animals; Calcium; Cardiovascular Agents; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Methylhydrazines; Myocytes, Cardiac; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Trimetazidine; Up-Regulation; Vasodilator Agents | 2002 |
[Biochemical mechanisms of mildronate action during ischemic stress].
Topics: Animals; Cardiovascular Agents; Carnitine; Clinical Trials as Topic; Humans; Methylhydrazines; Myocardial Ischemia; Myocardium; Oxidative Stress; Treatment Outcome | 2004 |
Mildronate: an antiischemic drug for neurological indications.
Topics: Animals; Cardiovascular Agents; Drug Evaluation; Humans; Ischemia; Ketone Bodies; Methylhydrazines; Models, Biological; Neuropharmacology; Nitric Oxide; Toxicology | 2005 |
[[Meldonium in treatment of patients with myocardial infarction].
Topics: Cardiotonic Agents; Cardiovascular Agents; Humans; Metabolism; Methylhydrazines; Myocardial Infarction; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity.
Topics: Animals; Biomarkers; Cardiotonic Agents; Cardiovascular Agents; Cardiovascular Diseases; Humans; Methylhydrazines; Myocardium | 2016 |
[Unsolved problems of cytoprotective therapy in patients with coronary heart disease].
Topics: Cardiotonic Agents; Cardiovascular Agents; Coronary Disease; Humans; Methylhydrazines; Trimetazidine | 2015 |
18 trial(s) available for 3-(2,2,2-trimethylhydrazine)propionate and cardiovascular agents
| Article | Year |
|---|---|
[The use of mildronat with stenocardia patients].
Topics: Adult; Angina Pectoris; Cardiovascular Agents; Exercise Test; Humans; Male; Methylhydrazines; Middle Aged; Physical Endurance; Randomized Controlled Trials as Topic; Spirometry | 1989 |
[Mildronate in combined treatment of chronic cardiac insufficiency].
Topics: Cardiac Output; Cardiovascular Agents; Diuretics; Drug Therapy, Combination; Echocardiography; Exercise Tolerance; Follow-Up Studies; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Safety; Treatment Outcome; Vasodilator Agents | 1999 |
[The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction].
Topics: Adrenergic beta-Antagonists; Atenolol; Cardiovascular Agents; Drug Therapy, Combination; Humans; Male; Methylhydrazines; Middle Aged; Mitochondrial Trifunctional Protein; Multienzyme Complexes; Myocardial Infarction; Ventricular Dysfunction, Left | 2003 |
[Effects of metabolic triad (25% polarizing solution, mildronat, preductal MR) in acute myocardial infarction].
Topics: Adult; Aged; Cardiovascular Agents; Drug Therapy, Combination; Female; Glucose; Humans; Insulin; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Potassium; Trimetazidine; Vasodilator Agents | 2006 |
[Comparative trial of efficacy of trimethasidine MB and 3-(2,2,2-trimethylhydrasine) propionate dihydrate in chronic heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Chronic Disease; Combined Modality Therapy; Diuretics; Drug Administration Schedule; Female; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Positron-Emission Tomography; Trimetazidine; Vasodilator Agents; Ventricular Dysfunction, Left | 2007 |
[The use of mildronate in combined therapy of postinfarction chronic heart failure in patients with type 2 diabetes mellitus].
Topics: Cardiovascular Agents; Chronic Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Prospective Studies | 2007 |
[Mildronate effects on oxidant stress in type 2 diabetic patients with diabetic peripheral (sensomotor) neuropathy].
Topics: Aged; Cardiovascular Agents; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Fasting; Female; Humans; Male; Methylhydrazines; Middle Aged; Oxidative Stress | 2008 |
Mildronate treatment alters γ-butyrobetaine and l-carnitine concentrations in healthy volunteers.
Topics: Adult; Betaine; Cardiovascular Agents; Carnitine; Diet; Female; Humans; Male; Meat; Methylhydrazines; Middle Aged; Young Adult | 2011 |
A dose-dependent improvement in exercise tolerance in patients with stable angina treated with mildronate: a clinical trial "MILSS I".
Topics: Adult; Aged; Aged, 80 and over; Angina, Stable; Cardiovascular Agents; Dose-Response Relationship, Drug; Exercise Tolerance; Female; Humans; Male; Methylhydrazines; Middle Aged; Treatment Outcome | 2011 |
Meldonium decreases the diet-increased plasma levels of trimethylamine N-oxide, a metabolite associated with atherosclerosis.
Topics: Adult; Atherosclerosis; Cardiovascular Agents; Carnitine; Diet; Female; HEK293 Cells; Humans; Male; Methylamines; Methylhydrazines; Organic Cation Transport Proteins; Seafood; Solute Carrier Family 22 Member 5 | 2013 |
Efficacy and safety of mildronate for acute ischemic stroke: a randomized, double-blind, active-controlled phase II multicenter trial.
Topics: Aged; Brain Ischemia; Cardiovascular Agents; Double-Blind Method; Female; Humans; Male; Methylhydrazines; Middle Aged; Stroke; Treatment Outcome | 2013 |
[Role of pFox inhibitors in the treatment of patients with acute myocardial ischemia].
Topics: Administration, Oral; Aged; Cardiovascular Agents; Dose-Response Relationship, Drug; Electrocardiography; Exercise Tolerance; Female; Forkhead Transcription Factors; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Prospective Studies; Treatment Outcome | 2014 |
[Use of meldonium in the combination treatment of patients with heart failure in the early postinfarction period].
Topics: Aged; Cardiovascular Agents; Diastole; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Injections, Intravenous; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Systole; Treatment Outcome | 2014 |
[Using meldonium to improve the adaptation of patients with cardiovascular disease to the effects of heat and correction of associated oxidative stress].
Topics: Adaptation, Physiological; Adult; Aged; Antioxidants; Cardiovascular Agents; Cardiovascular Diseases; Drug Monitoring; Female; Hemodynamics; Hot Temperature; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Methylhydrazines; Middle Aged; Oxidative Stress; Quality of Life; Superoxide Dismutase; Treatment Outcome | 2014 |
[The ability to use meldonium as adaptogen in winter in patients with cardiovascular disease].
Topics: Adjuvants, Immunologic; Aged; Carbohydrate Metabolism; Cardiovascular Agents; Cardiovascular Diseases; Cold Temperature; Drug Monitoring; Drug Therapy, Combination; Female; Hemodynamics; Humans; Lipid Metabolism; Male; Methylhydrazines; Middle Aged; Seasons; Treatment Outcome | 2014 |
[Efficiency of meldonium in the complex therapy of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Cardiovascular Agents; Coronary Angiography; Diastole; Drug Administration Routes; Drug Monitoring; Electrocardiography; Female; Humans; Male; Methylhydrazines; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Treatment Outcome; Ventricular Function, Left | 2014 |
Single- and Multiple-dose Pharmacokinetic, Safety and Tolerability Study of Mildronate Injection in Healthy Chinese Subjects Pharmacokinetic of Mildronate Injection.
Topics: Adult; Asian People; Cardiovascular Agents; China; Chromatography, Liquid; Female; Healthy Volunteers; Humans; Injections; Male; Methylhydrazines; Tandem Mass Spectrometry; Young Adult | 2016 |
[Effects of Meldonium in Early Postmyocardial Infarction Period].
Topics: Adult; Aged; Cardiovascular Agents; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Time Factors; Treatment Outcome | 2015 |
53 other study(ies) available for 3-(2,2,2-trimethylhydrazine)propionate and cardiovascular agents
| Article | Year |
|---|---|
[Erythrocyte functional activity in patients with heart failure and the possible means for its correction].
Topics: Adult; Aged; Cardiovascular Agents; Chronic Disease; Drug Therapy, Combination; Erythrocytes; Heart Failure; Hemodynamics; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia | 1992 |
[The efficacy of the mildronate treatment of patients with ischemic stroke].
Topics: Aged; Brain Ischemia; Cardiovascular Agents; Drug Evaluation; Female; Hemodynamics; Humans; Male; Methylhydrazines; Middle Aged; Remission Induction; Time Factors | 1991 |
[Effects of mildronate (quaterin) on hemodynamics in spontaneous and artificial heart rhythm in patients with ischemic heart disease].
Topics: Adult; Aged; Aged, 80 and over; Cardiac Pacing, Artificial; Cardiovascular Agents; Coronary Disease; Electrocardiography; Female; Heart Rate; Hemodynamics; Humans; Male; Methylhydrazines; Middle Aged | 1990 |
[Effects of mildronate on hemoglobin ligand spectrum in patients with ischemic heart disease complicated by coronary insufficiency].
Topics: Aged; Cardiovascular Agents; Coronary Disease; Heart Failure; Hemoglobins; Humans; Ligands; Male; Methemoglobin; Methylhydrazines; Middle Aged; Oxyhemoglobins | 1990 |
[Method of studying the effects of pharmacological substances on work capacity of animals in hypobaric hypoxia].
Topics: Amphetamine; Animals; Antioxidants; Atmosphere Exposure Chambers; Atmospheric Pressure; Benzimidazoles; Butylated Hydroxytoluene; Cardiovascular Agents; Hypoxia; Methylhydrazines; Mice; Physical Endurance; Posture; Swimming | 1990 |
Cardioprotective profile of MET-88, an inhibitor of carnitine synthesis, and insulin during hypoxia in isolated perfused rat hearts.
Topics: Administration, Oral; Animals; Cardiovascular Agents; Carnitine; Coronary Circulation; Glucose; Glycolysis; Heart; Hypoglycemic Agents; Hypoxia; In Vitro Techniques; Insulin; Lactic Acid; Male; Methylhydrazines; Myocardial Contraction; Oxidation-Reduction; Palmitates; Phosphates; Rats; Rats, Sprague-Dawley | 1998 |
Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2, 2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney.
Topics: Animals; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Fibroblasts; In Vitro Techniques; Kidney; Male; Methylhydrazines; Mice; Mice, Inbred C57BL; Mitochondria, Heart; Myocardium; Rats; Rats, Sprague-Dawley | 1999 |
[Effect of mildronate on life quality of patients with chronic heart failure].
Topics: Administration, Oral; Adult; Cardiovascular Agents; Chronic Disease; Female; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia; Patient Satisfaction; Quality of Life; Stroke Volume; Treatment Outcome | 1999 |
Beneficial effects of MET-88 on left ventricular dysfunction and hypertrophy with volume overload in rats.
Topics: Animals; Body Weight; Cardiac Volume; Cardiomegaly; Cardiovascular Agents; Heart; Hemodynamics; Male; Methylhydrazines; Organ Size; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Renin; Ventricular Dysfunction, Left | 1999 |
Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Body Weight; Cardiovascular Agents; gamma-Butyrobetaine Dioxygenase; Heart Failure; Heart Ventricles; Hemodynamics; Lactic Acid; Male; Methylhydrazines; Mixed Function Oxygenases; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Survival Rate | 2000 |
Pharmacokinetics and biological fate of 3-(2,2, 2-trimethylhydrazinium)propionate dihydrate (MET-88), a novel cardioprotective agent, in rats.
Topics: Animals; Carbon Radioisotopes; Cardiovascular Agents; Liver; Male; Metabolic Clearance Rate; Methylhydrazines; Perfusion; Protective Agents; Rats; Rats, Sprague-Dawley | 2000 |
MET-88, a gamma-butyrobetaine hydroxylase inhibitor, improves cardiac SR Ca2+ uptake activity in rats with congestive heart failure following myocardial infarction.
Topics: Adenine Nucleotides; Animals; Calcium; Captopril; Cardiovascular Agents; Energy Metabolism; Enzyme Inhibitors; gamma-Butyrobetaine Dioxygenase; Heart; Heart Failure; In Vitro Techniques; Male; Methylhydrazines; Mixed Function Oxygenases; Myocardial Infarction; Myocardium; Rats; Rats, Sprague-Dawley; Sarcoplasmic Reticulum | 2000 |
Inhibition of carnitine synthesis modulates protein contents of the cardiac sarcoplasmic reticulum Ca2+-ATPase and hexokinase type I in rat hearts with myocardial infarction.
Topics: Animals; Calcium-Transporting ATPases; Cardiovascular Agents; Carnitine; Hexokinase; Isoenzymes; Male; Methylhydrazines; Myocardial Infarction; Myocardium; Rats; Rats, Sprague-Dawley; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2000 |
[Achievements in the diagnosis and treatment of immune myocarditis].
Topics: Acute Disease; Adjuvants, Immunologic; Autoantibodies; Autoantigens; Autoimmune Diseases; B-Lymphocytes; Cardiovascular Agents; Chronic Disease; DNA; Humans; Immunoglobulin G; Immunoglobulin M; Immunosuppressive Agents; Methylhydrazines; Myocarditis; Myocardium; Recurrence; T-Lymphocytes; Virus Diseases | 2003 |
Fatty acid oxidation and related gene expression in heart depleted of carnitine by mildronate treatment in the rat.
Topics: Animals; Biological Transport; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Esterification; Fatty Acids; Gene Expression Regulation; In Vitro Techniques; Lipoprotein Lipase; Male; Methylhydrazines; Mitochondria, Heart; Myocardium; Oxidation-Reduction; Oxygen Consumption; Palmitic Acid; Perfusion; Rats; Rats, Wistar; RNA, Messenger; Triglycerides | 2004 |
Carnitine depletion in rat pups from mothers given mildronate: a model of carnitine deficiency in late fetal and neonatal life.
Topics: Animals; Animals, Newborn; Cardiovascular Agents; Carnitine; Female; Heart; Lactation; Liver; Methylhydrazines; Milk; Muscles; Palmitates; Pregnancy; Rats; Rats, Sprague-Dawley; Tissue Distribution; Triglycerides | 2005 |
Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5).
Topics: Aged; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Agents; Cell Line; Dogs; Endothelial Cells; Female; Genotype; Humans; Male; Methylhydrazines; Middle Aged; Myocardium; Organic Cation Transport Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Solute Carrier Family 22 Member 5; Spironolactone; Transfection; Verapamil | 2006 |
[Neuroprotective treatment of patients with normal tension glaucoma].
Topics: Adult; Aged; Cardiovascular Agents; Female; Glaucoma; Humans; Intraocular Pressure; Lipid Peroxidation; Male; Methylhydrazines; Middle Aged; Optic Nerve; Optic Neuropathy, Ischemic | 2006 |
Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics.
Topics: Angina Pectoris; Animals; Blood Pressure; Body Weight; Cardiovascular Agents; Fatty Acids; Female; Heart Rate; Methylhydrazines; Myocardial Infarction; Oxidation-Reduction; Rats; Rats, Sprague-Dawley | 2006 |
[Change of concentration endothelin-1 in rats on a background of alcohol and /or mildronate treatment].
Topics: Alcohol Drinking; Animals; Cardiomyopathy, Alcoholic; Cardiovascular Agents; Endothelin-1; Ethanol; Male; Methylhydrazines; Rats; Rats, Inbred Strains | 2006 |
[Change of concentration of L-carnitine in blood and other tissues in rats on a background of the alcohol intake and influence of mildronate on its level].
Topics: Alcoholism; Animals; Cardiovascular Agents; Carnitine; Ethanol; Male; Methylhydrazines; Rats; Rats, Inbred Strains; Tissue Distribution | 2006 |
Protection of azidothymidine-induced cardiopathology in mice by mildronate, a mitochondria-targeted drug.
Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Heart Diseases; Methylhydrazines; Mice; Mice, Inbred ICR; Mitochondria; Zidovudine | 2006 |
[Mildronate in geriatric patients with cardiac failure].
Topics: Age Factors; Aged; Aged, 80 and over; Blood Pressure; Cardiovascular Agents; Female; Follow-Up Studies; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Contraction; Quality of Life; Treatment Outcome | 2006 |
Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction.
Topics: Animals; Betaine; Cardiovascular Agents; Carnitine; Chromatography, High Pressure Liquid; Coronary Circulation; gamma-Butyrobetaine Dioxygenase; In Vitro Techniques; Injections, Intraperitoneal; Male; Methylhydrazines; Myocardial Infarction; Myocardium; Rats; Rats, Wistar | 2006 |
Determination of mildronate in human plasma and urine by liquid chromatography-tandem mass spectrometry.
Topics: Cardiotonic Agents; Cardiovascular Agents; Chromatography, High Pressure Liquid; Humans; Methylhydrazines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2007 |
[Changes in fatty acids content in blood red cells of patients with iron-deficiency anemia treated with sorbifer and mildronate].
Topics: Anemia, Iron-Deficiency; Cardiomyopathies; Cardiovascular Agents; Drug Therapy, Combination; Erythrocytes; Fatty Acids; Follow-Up Studies; Humans; Methylhydrazines; Middle Aged; Treatment Outcome; Vitamin E; Vitamins | 2008 |
Mildronate, a regulator of energy metabolism, reduces atherosclerosis in apoE/LDLR-/- mice.
Topics: Animals; Aorta; Atherosclerosis; Betaine; Cardiovascular Agents; Carnitine; Energy Metabolism; Female; Lipids; Male; Methylhydrazines; Mice; Mice, Knockout; Rats; Rats, Wistar | 2009 |
[Clinical condition of patients with persistent form of atrial fibrillation before and after cardioversion].
Topics: Atrial Fibrillation; Cardiovascular Agents; Echocardiography, Doppler; Electric Countershock; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Heart Rate; Humans; Injections, Intravenous; Inosine Diphosphate; Male; Methylhydrazines; Middle Aged; Quality of Life; Stroke Volume; Treatment Outcome | 2009 |
Protective effects of mildronate in an experimental model of type 2 diabetes in Goto-Kakizaki rats.
Topics: 3-Hydroxybutyric Acid; Administration, Oral; Animals; Blood Glucose; Cardiovascular Agents; Carnitine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Fructosamine; Heart; Hyperalgesia; Hypoglycemic Agents; In Vitro Techniques; Lipids; Male; Methylhydrazines; Myocardial Ischemia; Pain Threshold; Rats; Rats, Wistar | 2009 |
Effects of long-term mildronate treatment on cardiac and liver functions in rats.
Topics: Animals; Betaine; Biomarkers; Blood Glucose; Body Weight; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Dose-Response Relationship, Drug; Glucose; Heart; Hemodynamics; Lipids; Liver; Liver Glycogen; Male; Methylhydrazines; Myocardium; Rats; Rats, Wistar; Time Factors; Toxicity Tests, Chronic | 2009 |
Inhibition of carnitine acetyltransferase by mildronate, a regulator of energy metabolism.
Topics: Animals; Binding Sites; Biocatalysis; Cardiovascular Agents; Carnitine O-Acetyltransferase; Columbidae; Dose-Response Relationship, Drug; Energy Metabolism; Enzyme Inhibitors; Magnetic Resonance Spectroscopy; Methylhydrazines; Molecular Dynamics Simulation; Structure-Activity Relationship; Substrate Specificity | 2009 |
Determination of mildronate by LC-MS/MS and its application to a pharmacokinetic study in healthy Chinese volunteers.
Topics: Cardiovascular Agents; Chromatography, Liquid; Humans; Linear Models; Methylhydrazines; Sensitivity and Specificity; Tandem Mass Spectrometry | 2010 |
Administration of L-carnitine and mildronate improves endothelial function and decreases mortality in hypertensive Dahl rats.
Topics: Animals; Cardiovascular Agents; Carnitine; Endothelium, Vascular; Hypertension; Male; Methylhydrazines; Rats; Rats, Inbred Dahl; Sodium Chloride, Dietary; Survival Rate; Vitamin B Complex | 2011 |
The cardioprotective effect of mildronate is diminished after co-treatment with L-carnitine.
Topics: Animals; Betaine; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Chromatography, Liquid; Drug Interactions; Fatty Acids; Male; Methylhydrazines; Mitochondria, Heart; Mitochondrial Membranes; Myocardial Infarction; Myocardial Reperfusion Injury; Rats; Rats, Wistar; Tandem Mass Spectrometry; Vitamin B Complex | 2012 |
Mildronate as a regulator of protein expression in a rat model of Parkinson's disease.
Topics: Animals; Cardiovascular Agents; Corpus Striatum; Disease Models, Animal; Glial Cell Line-Derived Neurotrophic Factor; HSP70 Heat-Shock Proteins; Male; Methylhydrazines; Neural Cell Adhesion Molecules; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Protein Biosynthesis; Rats; Rats, Wistar; Substantia Nigra | 2011 |
[Mildronat--treatment of cardio-neurologic pathology in ischemia and hypoxia].
Topics: Cardiovascular Agents; Cardiovascular Diseases; Cerebrovascular Circulation; Cerebrovascular Disorders; Energy Metabolism; Humans; Hypoxia; Ischemia; Methylhydrazines; Randomized Controlled Trials as Topic | 2012 |
Elevated vascular γ-butyrobetaine levels attenuate the development of high glucose-induced endothelial dysfunction.
Topics: Animals; Aorta; Betaine; Cardiovascular Agents; Carnitine; Drug Therapy, Combination; Endothelium, Vascular; Glucose; Male; Methylhydrazines; Rats; Rats, Wistar | 2013 |
[Efficiency of mildronate in rats of different age with experimental-induced myocardial ischemia].
Topics: 2,3-Diphosphoglycerate; Adenosine Triphosphate; Age Factors; Animals; Cardiovascular Agents; Creatine Kinase; Decarboxylation; Energy Metabolism; Glycolysis; Isoenzymes; L-Lactate Dehydrogenase; Male; Methylhydrazines; Myocardial Ischemia; Myocytes, Cardiac; Pyruvates; Rats; Rats, Wistar | 2013 |
[Mildronate in the treatment of transitory ischemic attacks].
Topics: Attention; Cardiovascular Agents; Disease Progression; Free Radical Scavengers; Humans; Ischemic Attack, Transient; Lipid Peroxidation; Magnetic Resonance Imaging; Memory; Methylhydrazines; Psychometrics; Treatment Outcome; Ultrasonography, Doppler, Transcranial | 2013 |
Microencapsulation of mildronate in biodegradable and non-biodegradable polymers.
Topics: Animals; Capsules; Cardiovascular Agents; Kinetics; Lactic Acid; Male; Methylhydrazines; Polyesters; Polymers; Polystyrenes; Rabbits | 2014 |
[Cytoprotectors and their application in sports medicine].
Topics: Adaptation, Physiological; Athletes; Biological Availability; Cardiovascular Agents; Cytoprotection; Energy Metabolism; Humans; Mental Fatigue; Methylhydrazines; Nitric Oxide; Physical Endurance; Psychomotor Performance | 2013 |
Effect of experimental and sample factors on dehydration kinetics of mildronate dihydrate: mechanism of dehydration and determination of kinetic parameters.
Topics: Cardiovascular Agents; Kinetics; Methylhydrazines; Particle Size; Water | 2014 |
[Clinical experience of application mildronate at recovery treatment of patients with displazia connecting fabric].
Topics: Adult; Asthenia; Cardiovascular Agents; Connective Tissue Diseases; Drug Administration Routes; Drug Monitoring; Exercise Tolerance; Female; Heart Diseases; Heart Function Tests; Humans; Male; Methylhydrazines; Myocardial Contraction; Treatment Outcome | 2014 |
[Endothelial dysfunction as a marker of vascular aging syndrome on the background of hypertension, coronary heart disease, gout and obesity].
Topics: Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Cardiovascular Agents; Carotid Arteries; Coronary Disease; Elasticity; Endothelium, Vascular; Female; Gout; Humans; Hypertension; Losartan; Male; Methylhydrazines; Middle Aged; Obesity; Severity of Illness Index; Tunica Intima; Tunica Media; Vascular Stiffness | 2013 |
Sixty seconds on . . . meldonium.
Topics: Cardiovascular Agents; Doping in Sports; Humans; Methylhydrazines; Performance-Enhancing Substances; Substance Abuse Detection | 2016 |
A tennis lesson: sharp practice in the science behind the Sharapova case.
Topics: Athletes; Cardiovascular Agents; Carnitine; Doping in Sports; Female; Heart; Humans; Methylhydrazines; Muscle, Skeletal; Performance-Enhancing Substances; Tennis | 2016 |
The unusual pharmacokinetics of meldonium: Implications for doping.
Topics: Animals; Cardiovascular Agents; Doping in Sports; Humans; Methylhydrazines; Solute Carrier Family 22 Member 5 | 2016 |
Meldonium (Mildronate): Primum nоn nocere.
Topics: Adjuvants, Immunologic; Animals; Cardiovascular Agents; Cardiovascular Diseases; Carnitine; Humans; Methylhydrazines; Randomized Controlled Trials as Topic | 2016 |
[Clinical and Economic Aspects of Meldonium as Part of Physical Rehabilitation Programs in Patients With Coronary Heart Disease After Percutaneous Coronary Interventions].
Topics: Cardiovascular Agents; Coronary Disease; Exercise Test; Exercise Tolerance; Female; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Treatment Outcome | 2016 |
[Efficacy of Short-Term Therapy With Meldonium in Patients With Chronic Heart Failure of Ischemic Etiology and Type 2 Diabetes Mellitus].
Topics: Aged; Cardiovascular Agents; Chronic Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Heart Rate; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia | 2017 |
A fatty acid analogue targeting mitochondria exerts a plasma triacylglycerol lowering effect in rats with impaired carnitine biosynthesis.
Topics: Animals; Cardiovascular Agents; Carnitine; Fatty Acids; Liver; Male; Methylhydrazines; Mitochondria; Oxidation-Reduction; Rats; Rats, Wistar; Triglycerides | 2018 |
Meldonium long-term excretion period and pharmacokinetics in blood and urine of healthy athlete volunteers.
Topics: Administration, Oral; Adult; Athletes; Cardiovascular Agents; Doping in Sports; Female; Healthy Volunteers; Humans; Male; Methylhydrazines; Substance Abuse Detection; Young Adult | 2019 |
Effect of l-carnitine and mildronate on the mitochondrial metabolism of heart and bacterial composition of the gut microbiome in ageing mice.
Topics: Aging; Animals; Bifidobacterium; Cardiovascular Agents; Carnitine; DNA, Mitochondrial; Female; Gastrointestinal Microbiome; Male; Methylhydrazines; Mice; Mice, Inbred C57BL; Mitochondria, Heart | 2022 |